secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2022-04-11T23:59:59+00:00
Accession:  0001171843-22-002529
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose appoints Philippe Ledru as CCO; CFO Jotin Marango resigns
----------------------------------------------------------------

- Philippe Ledru appointed CCO effective April 6, 2022; base salary $410K with up to 40% bonus.
- Dr. Jotin Marango resigns as CFO/CBO to pursue other opportunity; CEO Dr. Rice assumes CAO role.
- Ledru receives a stock option grant for 600,000 common shares under Aptose's 2021 Stock Incentive Plan.
- Ledru previously held senior commercial roles at Merck and Novartis, including oncology pipeline leadership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184322002529/0001171843-22-002529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184322002529/f8k_041122.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-002529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer